# Institut Català d'Oncologia

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/institut-catala-d-oncologia/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 48 |
| Citations | 1,717,325 |
| City | Barcelona |
| Country | ES |
| Description | Institut Català d'Oncologia is a research organisation in Barcelona, ES. OpenAlex records 14,735 works and 1,717,325 citations for it. 2,724 researchers list it as their most recent affiliation. |
| Homepage | https://ico.gencat.cat |
| OpenAlex ID | https://openalex.org/I4210107147 |
| Researchers | 2,724 |
| ROR ID | https://ror.org/01j1eb875 |
| Type | government |
| Works | 14,735 |

## University papers

Showing 12 of 24.

- [Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice-guidelines-for/)
- [Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/soft-tissue-and-visceral-sarcomas-esmo-euracan-genturis-clinical-practice/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice-guidelines-for/)
- [Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database](https://scholariq.org/papers/cancer-risks-by-gene-age-and-gender-in-6350-carriers-of-pathogenic-mismatch/)
- [Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/bone-sarcomas-esmo-paedcan-euracan-clinical-practice-guidelines-for-diagnosis/)
- [Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/gastrointestinal-stromal-tumours-esmo-euracan-genturis-clinical-practice/)
- [Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database](https://scholariq.org/papers/cancer-risk-and-survival-in-i-path-mmr-i-carriers-by-gene-and-gender-up-to-75/)
- [Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database](https://scholariq.org/papers/cancer-incidence-and-survival-in-lynch-syndrome-patients-receiving-colonoscopic/)
- [POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance](https://scholariq.org/papers/pole-and-pold1-mutations-in-529-kindred-with-familial-colorectal-cancer-and-or/)
- [Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”](https://scholariq.org/papers/corrections-to-soft-tissue-and-visceral-sarcomas-esmo-euracan-clinical-practice/)
- [Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”](https://scholariq.org/papers/corrections-to-gastrointestinal-stromal-tumours-esmo-euracan-clinical-practice/)
- [Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells](https://scholariq.org/papers/olive-oil-s-bitter-principle-reverses-acquired-autoresistance-to-trastuzumab/)

## University researchers

- [Mercé Peris](https://scholariq.org/researchers/merce-peris/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.